Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
- Citation:
- Breast Cancer Res Treat vol 188 (2) 477-87
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 2148
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA232760, U10CA180820 and UG1CA189859 (ECOG-ACRIN), U10CA180868 (NSABP/NRG Oncology), UG1CA189821 and U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Tufia C. Haddad Jun He Ciara C. O'Sullivan Beiyun Chen Donald Northfelt Amylou C. Dueck Karla V. Ballman Kathleen S. Tenner Hannah Linden Joseph A. Sparano Judith O. Hopkins Chamath De Silva Edith A. Perez Paul Haluska Matthew P. Goetz
- Networks:
- KAISER, LAPS-MN026, NY021, PR028, SCOR
- Study
- NCCTG-N0733
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: